ERCC1 expression in advanced colorectal cancer and matched liver metastases
| Autor: | Anne-Marie Kanstrup Fiehn, Jane Preuss Hasselby, Laerke Müller Olsen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Colorectal cancer Concordance Adenocarcinoma Pathology and Forensic Medicine Metastasis Biomarkers Tumor/analysis 03 medical and health sciences 0302 clinical medicine Liver Neoplasms/metabolism Internal medicine Colorectal Neoplasms/metabolism Immunohistochemistry/methods medicine Biomarkers Tumor Humans Endonucleases/analysis Aged Aged 80 and over Observer Variation business.industry Standard treatment Liver Neoplasms Gastrointestinal pathology DNA-Binding Proteins/analysis Cell Biology Middle Aged medicine.disease Endonucleases Primary tumor Immunohistochemistry DNA-Binding Proteins 030104 developmental biology Adenocarcinoma/metabolism 030220 oncology & carcinogenesis Female ERCC1 business Colorectal Neoplasms Kappa |
| Zdroj: | Olsen, L M, Fiehn, A-M K & Hasselby, J P 2020, ' ERCC1 expression in advanced colorectal cancer and matched liver metastases ', Pathology, Research and Practice, vol. 216, no. 3, 152826 . https://doi.org/10.1016/j.prp.2020.152826 |
| DOI: | 10.1016/j.prp.2020.152826 |
| Popis: | BACKGROUND: Platinum-based chemotherapy is part of the standard treatment for patients with colorectal cancer. ERCC1 is a potential predictive biomarker for platinum-based chemotherapy. The aim of this study was to examine interobserver agreement on ERCC1 protein expression in primary colorectal cancer as well as corresponding liver metastasis. Furthermore, comparison of ERCC1-expression in primary tumor and the corresponding liver metastasis was performed.METHODS: Forty patients with primary colorectal cancers and corresponding liver metastases were included. One slide was stained with the anti-ERCC1 antibody, 4F9 clone (DAKO) and evaluated by two gastrointestinal pathology consultants and a pathology registrar separately. Interobserver agreement was evaluated for primary tumors and liver metastases using kappa (κ) statistics. Discordant scorings were reviewed, and consensus was obtained. The expression in primary tumor was compared with the corresponding liver metastases.RESULTS: For the primary tumors agreement was found in 85% of the tumors corresponding to an unweighted kappa value of 0,79 (95% CI 0,64-0,94). For the liver metastases agreement was found in 76% corresponding to an unweighted kappa value of 0,64 (95% CI 0,49-0,79). When comparing primary tumors to the corresponding metastases, no concordance in ERCC1-expression was observed.CONCLUSION: Interobserver agreement of ERCC1 expression was good for both primary tumors and liver metastases, which is crucial for a potential predictive biomarker. As no concordance between primary tumor and liver metastases was found it seems to be of high importance to use tissue from actual tumor burden for evaluation of ERCC1 expression. Further studies and correlation to clinical outcome are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|